Feb. 27, 2020—Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.
Jan. 16, 2020—The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.
Nov. 7, 2019—GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.
Jun. 6, 2019—Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.
Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.
Oct. 25, 2018—An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.
Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Mar. 1, 2018—James Allison, PhD, whose work led to the development of cancer immunotherapies known as “checkpoint inhibitors,” will deliver the next Flexner Discovery Lecture on Thursday, March 8.